Product Name:
JAK1-pY1022
Product Number:
ab-pk126
Target Full Name: Protein-tyrosine kinase JAK1 Tyr-1022 phosphosite
Target Alias: EC 2.7.10.2; JAK1A; Janus kinase 1
Product Type Specific: JAK1 protein kinase phosphosite-specific polyclonal antibody for human JAK1 Y1022 phosphosite
Antibody Code: PK126
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y1022
Protein UniProt: P23458
Protein SigNET: JAK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: IgG
Antibody Immunogen Source: Peptide with amino acid sequence surrounding the human JAK1 Tyr-1022 phosphosite
Antibody Immunogen Sequence: KE(pY)YT
Antibody Immunogen Description: 5 amino acid phosphopeptide corresponding to the human JAK1 Y1022 phosphosite.
Production Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol
Storage Conditions: -20°C
Storage Stability: > 1 year
Product Use: Western blotting, Immunohistochemistry (IHC)
Antibody Dilution Recommended: 2 µg/mL
Antibody Potency: Strong
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse.
Antibody Positive Control: Y1022 phosphorylated JAK1
Antibody Specificity: High
Antibody Cross Reactivity: Ocassionally, strong cross-reactivity with a ~23 kDa protein and weaker cross-reactivity with a ~50 kDa protein can be detected.
Related Product 1: JAK2Selectide kinase substrate peptide (Cat. No.: PE-01BHR90)
Related Product 2: JAK3Selectide kinase substrate peptide (Cat. No.: PE-01BHS95)
Related Product 3: IRS1 (891-902) KinSub kinase substrate peptide (Cat. No.: PE-01AQD95)
Related Product 4: JAK1 expression antibody (Cat. No.: AB-NK084-3)
Related Product 5: JAK1 expression antibody (Cat. No.: AB-NK084-4)
Related Product 6: JAK1 expression antibody (Cat. No.: AB-NK084-5)
Related Product 7: JAK1 Y1034+Y1035 phosphorylation antibody (Cat. No.: AB-PK884)
Related Product 8: JAK1 T1107 phosphorylation antibody (Cat. No.: AB-PK895)
Related Product 9: Tyk2 Y292 phosphorylation antibody (Cat. No.: AB-PK846)
Related Product 10: Tyk2 Y1054+Y1055 phosphorylation antibody (Cat. No.: AB-PK845)
Scientific Background: JAK1 is a protein-tyrosine kinase of the TK group and JAKA family. It is a non-receptor kinase that functions in the IFN-alpha/beta/gamma intracellular signal pathway. It features seven conserved JAK homology (JH) domains. The C-terminal JH1 is the active tyrosine kinase domain, while the adjacent JH2 appears to be a nonfunctional "pseudokinase" domain with regulatory roles. JAK1 has also been shown to interact with the interleukin-2 (IL-2) receptor. It is essential for signaling for IL-2 family (IL-2, 7, 9, 15), IL-4 family (IL-4, 13), gp130 family (IL-6, LIF), and interferons (IFN-a/b) and IFN-g). The JAK1 protein is typically membrane-associated and is widely expressed across different tissues. JAK1 also functions upstream of STAT transcription factors, specifically STAT3, acting to activate the proteins and promote gene transcription. Phosphorylation of Tyr-940 inhibits phosphotransferase activity. JAK1 may be an oncoprotein (OP). Abnormal activity of STAT3 is implicated in the oncogenesis of several cancer types, including colorectal cancer and non-small cell lung cancer. JAK1 has been implicated in promoting the survival, invasion, and migration of colorectal cancer and non-small cell lung cancer cells due to over activation of STAT transcription factors resulting in the aberrant expression of certain downstream genes, such as Bcl-2, p21, p27, E-cadherin, VEGF, and MMPs. In addition, somatic mutations in the JAK1 gene have been observed in patients with acute myeloid leukemia (AML), including both T478S and V623A substitution mutations. The mutant JAK1 proteins displayed significantly enhanced activation of downstream STAT1 in response to type 1 interferon treatment, as well as increased activation of multiple dowstream intracellular signalling pathways. Truncating mutations of JAK1 have been observed in several cancer types, with 68% of the specimens coming from gynecologic cancers. Cancer cells with mutant truncated JAK1 protein are defective in IFN-gamma induced expression of LMP2 and TAP1, which inhibits the presentation of tumour antigens to be recognized by the immune system. Therefore, these truncating mutations are hypothesized to promote the ability of tumour cells to evade the immune system, enabling tumour survival. Piceatannol is a known JAK1 inhibitor. This description may include information annotated by UniProt and/or Google AI.